KR910019637A - 안정화 fgf 조성물 - Google Patents

안정화 fgf 조성물 Download PDF

Info

Publication number
KR910019637A
KR910019637A KR1019910007897A KR910007897A KR910019637A KR 910019637 A KR910019637 A KR 910019637A KR 1019910007897 A KR1019910007897 A KR 1019910007897A KR 910007897 A KR910007897 A KR 910007897A KR 910019637 A KR910019637 A KR 910019637A
Authority
KR
South Korea
Prior art keywords
fgf
sos
composition
mammal
disease
Prior art date
Application number
KR1019910007897A
Other languages
English (en)
Inventor
쥬다 포크만 모세즈
슁 유엔
스자보 산도르
Original Assignee
캐롤 웨인립
칠드런즈 메디칼 센터 코포레이션
윌리암 디. 테리
브라이암 앤드 위민즈 호스피탈 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캐롤 웨인립, 칠드런즈 메디칼 센터 코포레이션, 윌리암 디. 테리, 브라이암 앤드 위민즈 호스피탈 인크 filed Critical 캐롤 웨인립
Publication of KR910019637A publication Critical patent/KR910019637A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

안정화 FGF 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 SOS존재 및 부재하에 bFGF에 대한 고온효과를 나타낸다. 제2도는 SOS존재 및 부재하에 bFGF에 대한 산효과를 나타낸다. 제3도는 수크랄페이트 존재 및 부재하에 rhbFGF뮤테인 CS23에 대한 팹신 효과를 나타낸다.

Claims (27)

  1. 유효량의 SOS-안정화 FGF조성물을 포유동물에 투여함을 특징으로 하는 FGF- 반응성 질병을 갖는 포유동물의 치료방법.
  2. 유효량의 SOS-안정화 FGF조성물을 포유동물에 투여함을 특징으로 하는 위장관의 궤양성 질병을 갖는 포유동물의 치료방법.
  3. 제1항또는 제2항에 있어서, 조성물의 FGF성분이 천연 FGF또는 재조합 FGF의 군에서 선택되는 방법.
  4. 제 3항에 있어서, 재조합 FGF가 rhbFGF 뮤테인 CS23인 방법.
  5. 제 2항에 있어서, 위장관의 궤양성 질병이 국한성 회장염을 포함하는 방법.
  6. 제2항에 있어서, 위장관의 궤양성 질병이 궤양성 대장염을 포함하는 방법.
  7. 제2항에 있어서, 위장관의 궤양성 질병이 소화성 궤양을 포함하는 방법.
  8. 제7항에 있어서, 소화성 궤양이 십이지장 궤양인 방법.
  9. 제7항에 있어서, 소화성 궤양이 위궤양인 방법.
  10. 제3항에 있어서, 포유동물이 사람이고, 조성물이 경구투여되며, 조성물의 FGF단백질 성분이 양이 하루에 약 0.1μg~30mg인 방법.
  11. 제10항에 있어서, FGF 단백질 성분의 양이 하루에 약 1μg~3mg인 방법.
  12. 제10항에 있어서, FGF단백질 성분의 양이 하루에 약 10~300μg인 방법.
  13. 제3항에 있어서, 포유동물이 사람이고, 조성물이 경구토여되며, 조성물의 SOS성분의 양이 분할투여량으로 약 0.1~6g/일인 방법.
  14. FGF 및 SOS를 약학상 허용가능한 담체, 부형제 또는 희석재와 함께 함유함을 특징으로 하는 약학 조성물.
  15. 제14항에 있어서, FGF가 천연 FGF 또는 재조합 FGF의 군에서 선택되는 약학 조성물.
  16. 제15항에 있어서. 재조합 FGF가 rhbFGF뮤테인 CS23인 약학 조성물.
  17. 제16항에 있어서, FGF에 대한 SOS의 비가 약 1:1 중량~10.000:1중량인 약학 조성물.
  18. a)시료액을 SOS와 접촉시키고, b) 시료액을 안정화 FGF의 존재에 대해 분석함을 특징으로 하는 시료액내의 FGF의 존재를 측정하는 방법.
  19. 제18항에 있어서, 시료액이 요인 방법.
  20. 제18항에 있어서, 시료액이 뇌척수액인 방법.
  21. a)시료액을, SOS함유 칼럼과 접촉시키고, b)칼럼을 용출액과 접촉시켜 FGF를 용출시킴을 특징으로 하는 시료액에서 FGF를 분리하는 방법.
  22. 제21항에 있어서, 컬럼이 세파로스 비드르 더 함유하는 방법.
  23. 제21항에 있어서, 용출액이 NaCL및 아세트산으로 구성된 군에서 선택되는 방법.
  24. SOS를 조직 배양물의 성분으로 조합함을 특징으로 하는 조직배양물 내의 FGF를 안정화시키는 방법.
  25. FGF및 SOS의 FGF-반응성인 질병을 갖는 포유동물의 치료용 약제를 제조하기 위한 용도.
  26. FGF및 SOS를 함유함을 특징으로 하는 FGF-반응성인 질병을 갖는 포유동물의 치료용 약제.
  27. FGF를 SOS와 조합함을 특징으로 하는 FGF반응성인 질병을 갖는 포유동물의 치료용 약제의 제조법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910007897A 1990-05-15 1991-05-15 안정화 fgf 조성물 KR910019637A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/524,144 1990-05-15
US07/524,144 US5202311A (en) 1988-08-19 1990-05-15 Stabilized fgf composition

Publications (1)

Publication Number Publication Date
KR910019637A true KR910019637A (ko) 1991-12-19

Family

ID=24087954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910007897A KR910019637A (ko) 1990-05-15 1991-05-15 안정화 fgf 조성물

Country Status (13)

Country Link
US (1) US5202311A (ko)
EP (1) EP0457223A1 (ko)
JP (1) JPH04330017A (ko)
KR (1) KR910019637A (ko)
CN (1) CN1058149A (ko)
AU (1) AU637904B2 (ko)
CA (1) CA2042569A1 (ko)
FI (1) FI912348A (ko)
HU (1) HU208635B (ko)
IE (1) IE911655A1 (ko)
IL (1) IL98040A0 (ko)
NO (1) NO911861L (ko)
RU (1) RU2070722C1 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260071A (en) * 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
AU6794194A (en) * 1993-05-18 1994-12-20 Bukh Meditec A/S A method for the preparation of interferons
EP0702959B1 (en) 1993-05-31 2001-08-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US5942499A (en) * 1996-03-05 1999-08-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7482427B2 (en) * 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
EP2276458A1 (en) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
US9347037B2 (en) * 2013-02-11 2016-05-24 Evan Masataka Masutani Methods and apparatus for building complex 3D scaffolds and biomimetic scaffolds built therefrom
WO2017089016A1 (en) 2015-11-27 2017-06-01 Masarykova Univerzita Thermostable fgf2 polypeptide, use thereof
WO2020188019A1 (en) * 2019-03-20 2020-09-24 Reponex Pharmaceuticals A/S Targeting biological agents to mucosal defects of the gastrointestinal tract
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DE3628829C1 (de) * 1986-08-25 1988-02-11 Pantelis Bozoglou Naehmaschine zum Annaehen eines Gummibandes
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5175147A (en) * 1988-08-19 1992-12-29 Takeda Chemical Industries, Ltd Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
FR2644066B1 (fr) * 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof

Also Published As

Publication number Publication date
US5202311A (en) 1993-04-13
FI912348A (fi) 1991-11-16
AU637904B2 (en) 1993-06-10
NO911861D0 (no) 1991-05-14
AU7703091A (en) 1991-11-21
FI912348A0 (fi) 1991-05-14
RU2070722C1 (ru) 1996-12-20
NO911861L (no) 1991-11-18
HUT57061A (en) 1991-11-28
CN1058149A (zh) 1992-01-29
JPH04330017A (ja) 1992-11-18
EP0457223A1 (en) 1991-11-21
IL98040A0 (en) 1992-06-21
CA2042569A1 (en) 1991-11-16
HU208635B (en) 1993-12-28
IE911655A1 (en) 1991-11-20

Similar Documents

Publication Publication Date Title
KR910019637A (ko) 안정화 fgf 조성물
US5318957A (en) Method of stimulating angiogenesis
Goodwin Mechanism of action of nonsteroidal anti-inflammatory agents
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
KR920700040A (ko) 내산성 fgf 조성물 및 위장관의 궤양성 질병의 치료방법
KR920011519A (ko) 사람의 종양 괴사 인자 α에 대한 모노클로날 항체
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
DK0502925T3 (da) præparat til behandling af inflammatoriske tarmlidelser
KR920009846A (ko) 시클로펩티드
KR920700630A (ko) 발현-촉진/증강된 해열성반응
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
KR950013513A (ko) 약제 제조용 모에노마이신 및 이의 유도체, 및 모에노마이신 또는 이의 유도체를 함유하는 약제
KR920702225A (ko) 약학 조성물
KR910019621A (ko) 상승병용을 이용한 안고혈압 치료
ES2123004T3 (es) Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
EP0220966A3 (en) Purification method for proteins
ATE115859T1 (de) Neue pharmazeutische präparate sowie neue lactosylverbindungen und ihre herstellung.
Fauvelle et al. Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients
Kausz et al. Intraperitoneal erythropoietin in children on peritoneal dialysis: A study of pharmacokinetics and efficacy
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
Tillement et al. Effect of sodium chlorophenoxyisobutyrate on the binding of vitamin K antagonists to human albumin in vitro
Adelhøj et al. Effect of diazepam on drug absorption and gastric emptying in man
Al-Meshal et al. Cod liver oil inhibits indomethacin induced gastropathy without affecting its bioavailability and pharmacological activity

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid